Cargando…
Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease – a post-hoc analysis of the PARAT trial
BACKGROUND: Hyperkalemia is an infrequent but potentially serious complication of low molecular weight heparin (LMWH) use. While there are a number of trials comparing LMWH to unfractionated heparin (UFH) there is no comparison of the risk with LMWH versus placebo. Aim of the present post-hoc analys...
Autores principales: | Melzer, Nima, Bramlage, Peter, Michaelis, Hans-Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307893/ https://www.ncbi.nlm.nih.gov/pubmed/25480344 http://dx.doi.org/10.1186/1756-0500-7-880 |
Ejemplares similares
-
Comparison of 3,000 and 5,000 IU aXa/day certoparin in the prevention of deep-vein thrombosis after total hip replacement
por: Bramlage, Peter, et al.
Publicado: (2012) -
Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study
por: Jochberger, Stefan, et al.
Publicado: (2005) -
Anti-Xa activities following 5,000 IU and 7,500 IU of s.c. dalteparin in critically ill patients and 5,000 IU in medical patients: a prospective randomized study
por: Heinz, GH, et al.
Publicado: (2013) -
A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study
por: Dorsch, Oliver, et al.
Publicado: (2012) -
AXA Winterthur
por: Staff Association
Publicado: (2020)